Image

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market - Industry Trends and Forecast to 2028

  • Pharmaceutical
  • Upcoming Report
  • Oct 2021
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market, By Type (Afatinib, Trastuzumab, Olmesartan Medoxomil, Valsartan, Irbesartan, Telmisartan, Losartan, Eprosartan, Candesartan Cilexetil, Allisartan Isoproxil), Application (Squamous Cell Carcinoma of NSCLC, Adenocarcinoma of NSCLC, Large Cell Carcinoma of NSCLC, Left Ventricular Hypertrophy, Congestive Heart Failure, Atherosclerosis, High Blood Pressure, Others), Dosage (Tablet, Others), Route of Administration (Oral, Other), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy), Country (U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa) Industry Trends and Forecast to 2028

Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Market Analysis and Insights: Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Global non-peptide drugs of angiotensin II receptor antagonist market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 7.80% in the above mentioned forecast period.

Angiotensin II is a peptide hormone of the renin-angiotensin-aldosterone-system (RAAS) which occurs naturally. It has the capacity to cause vasoconstriction and also results in the increased blood pressure.

Rise in the prevalence of disorders such as hypertension, congestive heart failure and atherosclerosis, growing healthcare expenditure, increase use of the product in the treatment, supportive strategies and growing government fundingare the factors that will expand the non-peptide drugs of angiotensin II receptor antagonist market.

Rise in the research and development activities and emerging markets will provide beneficial opportunities for the non-peptide drugs of angiotensin II receptor antagonist market in the forecast period of 2021-2028.

However, high cost of medication and side effects associated with drugs are the factors that will hinder the market growth and will further challenge the non-peptide drugs of angiotensin II receptor antagonist market in the forecast period mentioned above.

This non-peptide drugs of angiotensin II receptor antagonist market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the non-peptide drugs of angiotensin II receptor antagonist market contact Data Bridge Market Research for anAnalyst Brief, our team will help you take an informed market decision to achieve market growth.

Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market Scope and Market Size

The non-peptide drugs of angiotensin II receptor antagonist market is segmented on the basis of type, application, dosage, route of administration and distribution channel. The growth amongst these segments will help you analyze meager growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • On the basis of type, the non-peptide drugs of angiotensin II receptor antagonist market is segmented intoafatinib, trastuzumab, olmesartan medoxomil, valsartan, irbesartan, telmisartan, losartan, eprosartan, candesartan cilexetil and allisartan isoproxil.
  • On the basis of application, the non-peptide drugs of angiotensin II receptor antagonist market is segmented intosquamous cell carcinoma of NSCLC, adenocarcinoma of NSCLC, large cell carcinoma of NSCLC,left ventricular hypertrophy, congestive heart failure, atherosclerosis, high blood pressureand others.
  • On the basis of dosage, the non-peptide drugs of angiotensin II receptor antagonist market is segmented into tablet and others.
  • On the basis of route of administration, thenon-peptide drugs of angiotensin II receptor antagonist market is segmented into oral and others.

Thenon-peptide drugs of angiotensin II receptor antagonist market is also segmented on the basis of distribution channel into hospital pharmacy, retail pharmacy and online pharmacy.

Non-Peptide Drugs of Angiotensin II Receptor Antagonist MarketCountry Level Analysis

Non-peptide drugs of angiotensin II receptor antagonist market is analyzed and market size information is provided by the country, type, application, dosage, route of administration and distribution channelas referenced above.

The countries covered in the non-peptide drugs of angiotensin II receptor antagonist market reportare the U.S., Canada, Mexico, Brazil, Argentina, Peru, Rest of South America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific, Saudi Arabia, U.A.E, Egypt, Israel, Kuwait, South Africa, Rest of Middle East and Africa.

North America dominates the non-peptide drugs of angiotensin II receptor antagonist market due to the presence of major key players, well-developed healthcare sector, high cost of drugs and advancement in treatment options in this region. Asia-Pacific is expected to grow during the forecast period 2021 to 2028 due to the increasing research and development activities, emerging markets, rising investment in the healthcare sector and growing government support.

The country section of the report also provides individual market impacting factors and changes in regulations in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

Non-peptide drugs of angiotensin II receptor antagonist market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist MarketShare Analysis

Non-peptide drugs of angiotensin II receptor antagonist market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, company strengths and weaknesses, product launch, clinical trials pipelines, product approvals, patents, product width and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the companies’ focus related toglobal non-peptide drugs of angiotensin II receptor antagonist market.

The major players covered in the non-peptide drugs of angiotensin II receptor antagonist market report are Novartis AG,Pfizer Inc.,Merck KGaA, Johnson & Johnson Private Limited, AstraZeneca, Lilly, Sanofi,Bayer AG,Bristol-Myers Squibb Company,Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc,Sun Pharmaceutical Industries Ltd.,Shenzhen salubris pharmaceuticals Limited, Mylan N.V.,Boehringer Ingelheim International GmbH., Aurobindo Pharma, Lupin, Alembic Pharmaceuticals Limited., Amneal Pharmaceuticals LLC., and BeiGene, among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Customization Available: Global Non-Peptide Drugs of Angiotensin II Receptor Antagonist Market

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Factbook) or can assist you in creating presentations from the data sets available in the report.


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

CHOOSE LICENCE TYPE
  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00
Why Choose Us
Unlocking New Opportunities on this Report Post Covid-19

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions



Frequently Asked Questions